Stocks · News reference
8-K filing — Humacyte, Inc. (HUMA)
Filed: 2026-09-28 AccNo: 0001818382-26-000011 Size: 311 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Humacyte Reports Accelerating Commercial Adoption, Reports 44% Increase In Hospitals Ordering Symvess To 49 In Q3 2026
Humacyte Says Interim Phase 3 Data For ATEV In Dialysis Access To Be Presented October 22, sBLA Filing Expected This Quarter
Barclays Initiates Coverage On Humacyte with Equal-Weight Rating, Announces Price Target of $0.5
Barclays analyst Christopher Pasquale initiates coverage on Humacyte (NASDAQ:HUMA) with a Equal-Weight rating and announces Price Target of $0.5.